Effectiveness of CAR-T treatment toward the potential risk of second malignancies

doi:10.3389/fimmu.2024.1384002

. 2024 May 2:15:1384002.

doi: 10.3389/fimmu.2024.1384002. eCollection 2024.

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Massimo Martino^{1

2}, Gaetana Porto^{1

2}, Giorgia Policastro^{1

2}, Caterina Alati^{2

3}, Barbara Loteta^{1

2}, Maria Caterina Micó^{1

2}, Clizia Argiró^{1

2}, Maria Altomonte^{2

4}, Tiziana Moscato^{1

2}, Demetrio Labate^{2

5}, Vincenzo Dattola^{2

6}, Carmelo Massimiliano Rao^{2

7}, Francesca Cogliandro^{1

2}, Filippo Antonio Canale^{1

2}, Virginia Naso^{1

2}, Gianfranco Filippelli⁸, Antonino Iaria⁹, Martina Pitea^{1

2}

Affiliations

¹ Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
² CAR-T Multidisciplinary Team, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
³ Hematology Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁴ Pharmacy Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁵ ICU Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁶ Neurology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁷ Cardiology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁸ Oncology Department, Hospital of Paola, Cosenza, Italy.
⁹ Oncology Unit, Melito Porto Salvo, Reggio Calabria, Italy.

PMID: 38756776
PMCID: PMC11096564
DOI: 10.3389/fimmu.2024.1384002

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Massimo Martino et al. Front Immunol. 2024.

. 2024 May 2:15:1384002.

doi: 10.3389/fimmu.2024.1384002. eCollection 2024.

Authors

Affiliations

¹ Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
² CAR-T Multidisciplinary Team, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
³ Hematology Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁴ Pharmacy Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁵ ICU Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁶ Neurology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁷ Cardiology Unit, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
⁸ Oncology Department, Hospital of Paola, Cosenza, Italy.
⁹ Oncology Unit, Melito Porto Salvo, Reggio Calabria, Italy.

PMID: 38756776
PMCID: PMC11096564
DOI: 10.3389/fimmu.2024.1384002

No abstract available

Keywords: car-t; follow-up; malignancies; second cancer; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Joy R, Phair K, O'Hara R, Brady D. Recentadvances and current challenges in CAR-T cell therapy. Biotechnol Lett. (2024) 46:115–26. doi: 10.1007/s10529-023-03461-0 - DOI - PubMed
1. Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. . (CAR-T) cells: Novelcell therapy for hematologicalmalignancies. Cancer Med. (2023) 12:7844–58. doi: 10.1002/cam4.5551 - DOI - PMC - PubMed
1. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione CA. Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute LymphoblasticLeukemia. Int J Mol Sci. (2021) 22:2150. doi: 10.3390/ijms22042150 - DOI - PMC - PubMed
1. Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and AllogeneicStem Cell TransplantBothHave a Place in LymphoidNeoplasms? Int J Mol Sci. (2023) 24:1045. doi: 10.3390/ijms24021045 - DOI - PMC - PubMed
1. Martino M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, et al. . Integrating CAR-T cell therapy into the management of DLBCL: whatwe are learning. Expert OpinBiolTher. (2023) 23:1277–85. doi: 10.1080/14712598.2023.2292634 - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Joy R, Phair K, O'Hara R, Brady D. Recentadvances and current challenges in CAR-T cell therapy. Biotechnol Lett. (2024) 46:115–26. doi: 10.1007/s10529-023-03461-0 - DOI - PubMed

[2] Joy R, Phair K, O'Hara R, Brady D. Recentadvances and current challenges in CAR-T cell therapy. Biotechnol Lett. (2024) 46:115–26. doi: 10.1007/s10529-023-03461-0 - DOI - PubMed

[3] Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. . (CAR-T) cells: Novelcell therapy for hematologicalmalignancies. Cancer Med. (2023) 12:7844–58. doi: 10.1002/cam4.5551 - DOI - PMC - PubMed

[4] Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. . (CAR-T) cells: Novelcell therapy for hematologicalmalignancies. Cancer Med. (2023) 12:7844–58. doi: 10.1002/cam4.5551 - DOI - PMC - PubMed

[5] Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione CA. Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute LymphoblasticLeukemia. Int J Mol Sci. (2021) 22:2150. doi: 10.3390/ijms22042150 - DOI - PMC - PubMed

[6] Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione CA. Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute LymphoblasticLeukemia. Int J Mol Sci. (2021) 22:2150. doi: 10.3390/ijms22042150 - DOI - PMC - PubMed

[7] Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and AllogeneicStem Cell TransplantBothHave a Place in LymphoidNeoplasms? Int J Mol Sci. (2023) 24:1045. doi: 10.3390/ijms24021045 - DOI - PMC - PubMed

[8] Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and AllogeneicStem Cell TransplantBothHave a Place in LymphoidNeoplasms? Int J Mol Sci. (2023) 24:1045. doi: 10.3390/ijms24021045 - DOI - PMC - PubMed

[9] Martino M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, et al. . Integrating CAR-T cell therapy into the management of DLBCL: whatwe are learning. Expert OpinBiolTher. (2023) 23:1277–85. doi: 10.1080/14712598.2023.2292634 - DOI - PubMed

[10] Martino M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, et al. . Integrating CAR-T cell therapy into the management of DLBCL: whatwe are learning. Expert OpinBiolTher. (2023) 23:1277–85. doi: 10.1080/14712598.2023.2292634 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Affiliations

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Authors

Affiliations

Conflict of interest statement

Similar articles

References

MeSH terms

LinkOut - more resources

Full Text Sources